Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).

Nick van Dijk,Alberto Gil Jimenez,Karīna Siliņa,Kees Hendricksen,Laura A. Smit,Jeantine de Feijter,Maurits L van Montfoort,Annegien Broeks,Yoni Lubeck,Karolina Sikorska,Thierry N. Boellaard,Pia Kvistborg,Daniel J. Vis,Erik Hooijberg,Ton N. M. Schumacher,Maries van den Broek,Lodewyk F. A. Wessels,Christian U. Blank,Bas W.G. van Rhijn,Michiel S. van der Heijden

Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).

2020

5020Background: Encouraging pathological complete response (pCR) rates were observed in trials testing neoadjuvant pembrolizumab or atezolizumab in urothelial cancer (UC). In cT3-4N0 tumors, pCR to...

Keywords:

urothelial cancer
Oncology
Ipilimumab
Internal medicine
Pathology
Nivolumab
Biomarker Analysis
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations